DE602007010108D1 - - Google Patents

Info

Publication number
DE602007010108D1
DE602007010108D1 DE602007010108T DE602007010108T DE602007010108D1 DE 602007010108 D1 DE602007010108 D1 DE 602007010108D1 DE 602007010108 T DE602007010108 T DE 602007010108T DE 602007010108 T DE602007010108 T DE 602007010108T DE 602007010108 D1 DE602007010108 D1 DE 602007010108D1
Authority
DE
Germany
Prior art keywords
determining
kits
subject
methods
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602007010108T
Other languages
German (de)
English (en)
Inventor
Nadir Arber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MEDICAL RES FUND OF TEL AVIV S
Original Assignee
MEDICAL RES FUND OF TEL AVIV S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MEDICAL RES FUND OF TEL AVIV S filed Critical MEDICAL RES FUND OF TEL AVIV S
Publication of DE602007010108D1 publication Critical patent/DE602007010108D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE602007010108T 2006-01-31 2007-01-31 Active DE602007010108D1 (https=)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76337806P 2006-01-31 2006-01-31
PCT/IL2007/000122 WO2007088537A2 (en) 2006-01-31 2007-01-31 Methods and kits for early detection of cancer or predisposition thereto

Publications (1)

Publication Number Publication Date
DE602007010108D1 true DE602007010108D1 (https=) 2010-12-09

Family

ID=38001788

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602007010108T Active DE602007010108D1 (https=) 2006-01-31 2007-01-31

Country Status (12)

Country Link
US (1) US9394569B2 (https=)
EP (1) EP1994410B1 (https=)
JP (1) JP5091163B2 (https=)
AT (1) ATE486285T1 (https=)
DE (1) DE602007010108D1 (https=)
DK (1) DK1994410T3 (https=)
ES (1) ES2355388T3 (https=)
IL (1) IL193097A (https=)
PL (1) PL1994410T3 (https=)
PT (1) PT1994410E (https=)
SI (1) SI1994410T1 (https=)
WO (1) WO2007088537A2 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE486285T1 (de) 2006-01-31 2010-11-15 Medical Res Fund Of Tel Aviv S Verfahren zur früherkennung von krebs
WO2009074988A1 (en) * 2007-12-10 2009-06-18 Medical Research Fund Of Tel Aviv Sourasky Medical Center Methods of diagnosing cancer
EP2358912B1 (en) * 2008-10-30 2016-10-12 Caris Life Sciences Switzerland Holdings GmbH Methods for assessing rna patterns
WO2011109440A1 (en) 2010-03-01 2011-09-09 Caris Life Sciences Luxembourg Holdings Biomarkers for theranostics
GB2463401B (en) * 2008-11-12 2014-01-29 Caris Life Sciences Luxembourg Holdings S A R L Characterizing prostate disorders by analysis of microvesicles
US20140148348A1 (en) 2010-01-13 2014-05-29 Christine Kuslich Dectection of gastrointestinal disorders
WO2011127219A1 (en) 2010-04-06 2011-10-13 Caris Life Sciences Luxembourg Holdings Circulating biomarkers for disease
AU2011256064B2 (en) 2010-05-21 2016-09-15 The Governors Of The University Of Alberta Methods for the assessment of colorectal cancer and colorectal polyps by measurement of metabolites in urine
EP3052651B1 (en) 2013-10-01 2019-11-27 Life Technologies Corporation Systems and methods for detecting structural variants
ES2939298T3 (es) 2017-05-21 2023-04-20 Medical Res Infrastructure & Health Services Fund Tel Aviv Medical Ct Combinación de marcadores para el diagnóstico del cáncer
EP3447154A1 (en) * 2017-08-23 2019-02-27 Instytut Genetyki Sadowej Jolanta Powierska - Czarny Method for detection of mutations, polymorphisms and specific dna sequences on dna matrices with dna imaging techniques for the use in medical diagnostics and forensic genetics
US20200408761A1 (en) 2018-02-28 2020-12-31 The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center Methods of diagnosing and treating bladder cancer
JP7462632B2 (ja) 2018-11-30 2024-04-05 カリス エムピーアイ インコーポレイテッド 次世代分子プロファイリング
CN110777213A (zh) * 2019-11-05 2020-02-11 武汉科技大学 一种潜伏期胃癌诊断试剂盒
WO2021112918A1 (en) 2019-12-02 2021-06-10 Caris Mpi, Inc. Pan-cancer platinum response predictor
US11840720B2 (en) 2019-12-23 2023-12-12 Metabolomic Technologies Inc. Urinary metabolomic biomarkers for detecting colorectal cancer and polyps

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07500411A (ja) * 1991-02-05 1995-01-12 ファロク　セィディ 癌胎児性抗原を検出するための簡易検査法
US5741650A (en) * 1996-01-30 1998-04-21 Exact Laboratories, Inc. Methods for detecting colon cancer from stool samples
US7081516B2 (en) * 2002-08-26 2006-07-25 Case Western Reserve University Methods for categorizing patients
EP1497642A2 (en) * 2002-03-19 2005-01-19 Tularik, Inc. Gene amplification in cancer
US20040097448A1 (en) * 2002-11-19 2004-05-20 Isis Pharmaceuticals Inc. Modulation of CD24 expression
WO2005024603A2 (en) * 2003-09-10 2005-03-17 The Board Of Regents Of The University Of Texas System Methods for detecting, diagnosing and treating human renal cell carcinoma
CA2549913A1 (en) * 2003-11-26 2005-06-16 The Ohio State University Research Foundation Polymorphic cd24 genotypes that are predictive of multiple sclerosis risk and progression
CA2453198A1 (en) * 2004-01-07 2005-07-07 Wei-Ping Min Quantification and generation of immune suppressive exosomes
US7666583B2 (en) * 2004-02-19 2010-02-23 Yale University Identification of cancer protein biomarkers using proteomic techniques
ATE486285T1 (de) 2006-01-31 2010-11-15 Medical Res Fund Of Tel Aviv S Verfahren zur früherkennung von krebs

Also Published As

Publication number Publication date
IL193097A0 (en) 2009-02-11
EP1994410B1 (en) 2010-10-27
JP5091163B2 (ja) 2012-12-05
US9394569B2 (en) 2016-07-19
SI1994410T1 (sl) 2011-03-31
PL1994410T3 (pl) 2011-12-30
ES2355388T3 (es) 2011-03-25
WO2007088537A2 (en) 2007-08-09
JP2009525041A (ja) 2009-07-09
DK1994410T3 (da) 2011-01-31
IL193097A (en) 2013-03-24
US20100062450A1 (en) 2010-03-11
ATE486285T1 (de) 2010-11-15
WO2007088537A3 (en) 2007-10-25
EP1994410A2 (en) 2008-11-26
PT1994410E (pt) 2011-01-10

Similar Documents

Publication Publication Date Title
DE602007010108D1 (https=)
EA200971079A1 (ru) ГЕНЕТИЧЕСКИЕ ВАРИАНТЫ В Chr5p12 И 10q26 В КАЧЕСТВЕ МАРКЕРОВ ДЛЯ ПРИМЕНЕНИЯ ПРИ ОЦЕНКЕ РИСКА, ДИАГНОСТИРОВАНИИ, ПРОГНОЗИРОВАНИИ И ЛЕЧЕНИИ РАКА ГРУДИ
WO2010062960A3 (en) METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNFα THERAPY IN INFLAMMATORY BOWEL DISEASE
WO2004097052A3 (en) Methods for prognosis and treatment of solid tumors
WO2008117314A3 (en) Genetic variants on chr2 and chr16 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
GB2463401B (en) Characterizing prostate disorders by analysis of microvesicles
WO2010056374A3 (en) Methods and compositions of molecular profiling for disease diagnostics
WO2010031056A3 (en) Methods and compositions for modulating ire1, src, and abl activity
IL192199A (en) Methods for estimating probabilistic measurements of clinical outcomes using a genomic profile
WO2006138275A3 (en) Compositions and methods for treating and diagnosing cancer
MX2009005651A (es) Marcadores geneticos para el manejo de riesgo de la arritmia cardiaca.
WO2006085984A3 (en) Immune cell biosensors and methods of using same
WO2012162660A3 (en) Methods using dna methylation for identifying a cell or a mixture of cells for prognosis and diagnosis of diseases, and for cell remediation therapies
WO2010036960A3 (en) Methods for treating, diagnosing, and monitoring lupus
WO2009047756A3 (en) Methods and kits for diagnosing lung cancer
WO2006076025A3 (en) Immune cell biosensors and methods of using same
EP2186912A3 (en) Materials and methods for assaying for methylation of CpG islands associated with genes in the evaluation of cancer
WO2008088860A3 (en) Polymorphisms in the egfr pathway as markers for cancer treatment
WO2007056523A3 (en) Methods for diagnosing and monitoring the progression of cancer
WO2007120955A3 (en) Genes affecting human memory performance
WO2006059252A3 (en) Methods and fluorinated compositions for treating amyloid-related diseases
WO2010020619A3 (en) Susceptibility to dasatinib
WO2006026074A3 (en) Atherosclerotic phenotype determinative genes and methods for using the same
WO2007067813A3 (en) Methods and compositions for assessing alterations in gene expression patterns in clinically normal tissues obtained from heterozygous carriers of mutant genes associated with cancer and methods of use thereof
EP1695092B8 (en) Diagnostic methods for therapeutic compounds and methods for monitoring azathioprine therapy